Benzodiazepine Taper Guideline Caps Reductions at 25% Biweekly

Like alcohol, benzodiazepines are one of the few substances where medical detox exists because stopping can kill you. A joint clinical practice guideline from 10 medical societies has now put specific numbers on how slowly to come off them, and the ceiling is as important as the floor.

The guideline recommends initial dose reductions of 5% to 10%. Every two to four weeks, medical professional should adjust in steps of 5% to 10%. They should never exceed 25% every 2 weeks. A full taper can take months and even years.

What the Guideline Is and Who Wrote It

The American Society of Addiction Medicine coordinated the guideline with nine other medical and professional societies. These included the American Academy of Family Physicians, the American Psychiatric Association, the American Geriatrics Society and the American College of Medical Toxicology. Development was funded by a US Food and Drug Administration grant.

It applies to adults who are outside palliative and end-of-life care. The June 2026 issue of American Family Physician provided a summary written by Maxwell Butler and Elizabeth Salisbury-Afshar of the University of Wisconsin-Madison School of Medicine and Public Health.

One caveat is important to remember for how much weight to give the numbers. Most recommendations are backed by expert consensus as opposed to trial evidence. The current trial evidence on benzodiazepine tapering is very limited. The guideline itself states there is no reliable criteria to accurately predict which individuals will struggle with a taper.

Why Medical Detox Matters for Benzodiazepines

Nearly 24 million patients are prescribed benzodiazepines in the United States. They’re used to treat anxiety, panic disorder, social phobia, insomnia and seizures. A person taking them exactly as directed can still end up becoming physically dependent.

It’s a distinction that can often be overlooked. Dependence is not an indicator of misuse. A person who has never taken more than prescribed still faces a significant risk of dangerous withdrawal if they suddenly stopped taking their medication.

The guideline is unambiguous. Benzodiazepines should never under any circumstance be abruptly discontinued in a patient likely to be physically dependent because of the risk of severe and potentially deadly withdrawal.

Who Is Actually at Risk

The guideline includes a risk table that is more useful than most people expect. It’s useful because it separates casual use from the pattern that produces dangerous withdrawal.

Use of three days a week or less rarely produces a clinically significant withdrawal at any dose. Use of four or more days a week for less than a month carries a lower but real risk. At one to three months of use four or more days a week, low doses stay lower risk while moderate to high doses cross into meaningful risk.

At three months or longer, taken four or more days a week, the risk applies at any dose and it climbs with both dose and duration. Withdrawal symptoms span body systems.

This can include elevated blood pressure, headaches, sweating, anxiety and panic, depression and irritability, palpitations, nausea and vomiting, tremors, muscle pain, sensory hypersensitivity, insomnia and nightmares and depersonalization. The dangerous ones, meaning seizures, delirium and psychosis, are typically associated with abruptly quitting high doses of the medication.

Risks on Both Sides of the Decision

The guideline frames this as a balance and not a directive to get everyone off benzodiazepines. Continuing long-term use carries major risks.

This includes falls and related injuries, memory and cognitive effects, motor vehicle accidents, oversedation, medication interactions, disrupted sleep, diversion, substance use disorder, overdose and suicidality. Overdose risk climbs when benzodiazepines have been combined with opioids or other central nervous system depressants.

Tapering carries its own risks. Beyond withdrawal, the guideline names recurrence of the condition the medication was originally treating and protracted withdrawal. Additionally, a taper handled badly can push someone toward counterfeit benzodiazepines from the illicit market, where fentanyl contamination is a documented hazard.

The guideline also notes that half-lives are unknown for some novel synthetic benzodiazepines circulating illicitly. This means it’s harder to anticipate withdrawal from these medications. That is a strong argument for all users to undergo supervised care and a stronger argument against a self-managed reduction.

How the Guideline Says to Approach It

Risks and benefits of continued use should be reassessed at least every 3 months or with each new prescription or renewal. Prescription drug monitoring program data should be reviewed.

Where resources are limited, the guideline says to prioritize people who are at highest risk. This includes people with cognitive concerns or recent falls, those with a substance use disorder or overdose risk and those on doses which are above the labeled maximum.

Before a taper starts, the guideline calls for shared decision-making with the patient and their care partners. It additionally calls for optimizing treatment for the underlying condition, checking the monitoring program and coordinating with any other clinician prescribing benzodiazepines, opioids or other controlled medications.

Psychosocial support such as cognitive behavioral therapy should also be offered or referred. The first reduction should sit at the lower end of the range at about 5%.

Patients get monitored after each reduction, and monitoring continues after the last dose because of protracted withdrawal. Check-ins can be virtual, including by phone.

When symptoms emerge, the guideline says to either pause or slow the taper rather than continue to push through. Other techniques include reducing by a percentage of the current dose rather than the original, which is known as hyperbolic tapering, and microtapering using liquid formulations.

Switching to a longer-acting benzodiazepine such as clonazepam is also an option, in particular for people taking alprazolam.

Reaching a lower dose may be enough. The goal of tapering is not always to get to zero.

Levels of Care and When to Escalate

Most benzodiazepine tapering happens in outpatient care over a long period and the guideline says so directly. More intensive care may be needed when a slow dose reduction cannot quickly manage the risk of harm or other conditions make tapering more difficult.

In practice that points toward inpatient withdrawal management for people with a history of withdrawal seizures or delirium, dependence on alcohol or opioids alongside benzodiazepines, unstable medical or psychiatric conditions or a previous taper that went badly.

ASAM criteria describe these intensities as Level 4 medically managed intensive inpatient care, Level 3.7 medically monitored inpatient care and Level 3.2 clinically managed residential care.

The guideline also suggests consulting a medical toxicologist, addiction specialist or clinical pharmacist for cases that are complex.

Finding Medical Detox and Tapering Support

Here are some questions to ponder asking as you consider a detox program to manage tapering. Does the detox program manage benzodiazepine tapering over time or only acute withdrawal?

Who will oversee the taper and how often are the doses reassessed? What happens if the symptoms become intolerable partway through? Does it treat co-occurring anxiety or a substance use disorder alongside the taper rather than after it?

If you take benzodiazepines and want to stop, the starting point is to have a conversation with the prescriber and not a self-directed reduction.

Detox.com’s directory lists medically supervised detox programs with details about substances treated, levels of care and insurance accepted. Call 800-996-6135Sponsored to learn more about specific treatment options near you.